|
| |
INTEGRAGEN BECOMES FIRST CERTIFIED FRENCH SERVICE PROVIDER FOR ILLUMINA
GOLDENGATE AND INFINIUM GENOTYPING
SAN DIEGO, June 18, 2007 – Concurrent with the annual European Human
Genetics Conference in Nice, France, Illumina, Inc. (NASDAQ:ILMN) announced
today that IntegraGen SA, a personalized healthcare company focused on the
development and commercialization of molecular diagnostic tests for complex
diseases and provider of genetic services, has received Illumina Certified
Service Provider (CSPro™) certification for GoldenGate® and Infinium® genotyping
technologies.
Illumina, a San Diego-based company, is a leading developer, manufacturer, and
marketer of next-generation life science tools and integrated systems for the
analysis of genetic variation and biological function. The GoldenGate assay is
Illumina’s first array-based platform that combines high-sample throughput, high
multiplexing, and single-site CpG resolution for DNA methylation profiling. The
Infinium Whole-Genome Genotyping BeadArray™ solution offers single or
multi-sample BeadChip formats and high-density architecture with the flexibility
to add additional custom SNP Assays.
“IntegraGen is a company dedicated to offering high-quality services to other
research institutes, either private or academic, and is the first laboratory in
France to achieve CSPro certification for GoldenGate and Infinium Genotyping,”
said Karen Possemato, Illumina’s Director of Corporate Marketing commented. “By
becoming a member of CSPro, they have further demonstrated their commitment to
the life science community, providing delivery of the highest-quality data
available for genetic analysis applications.”
Emmanuel Martin, IntegraGen’s Director of Services and Arrays said: “IntegraGen
is proud of its ability to leverage core competencies and provide genetic
services to the research community. Receiving Illumina CSPro certification is an
endorsement of both Illumina and IntegraGen’s commitment to quality, and
provides our customers with even greater confidence in our ability meet their
needs.”
As a customer of IntegraGen, Jessica Zucman-Rossi, M.D., Ph.D., has been using
Illumina technology in a pilot study for loss of heterozygosity (LOH) analysis
in liver tumors at the Human Polymorphism Study Center (CEPH) in Paris. “We also
chose Illumina technology to test for promoter methylation in liver tumors
because there were a large number of genes available for testing with this
system, and the ability to quantify methylation levels is a real advantage. My
team was able to analyze a large number of samples in each experiment, and the
time taken to generate results was short, generating a large amount of data.”
She added, “The results we attained were excellent, achieving methylation
profiling of 96 tumor samples on more than 1,500 CpG. The data are robust, and
we are currently preparing a second series of samples.”
About Illumina CSPro
Illumina CSPro is a collaborative service provider partnership dedicated to
ensuring the delivery of the highest-quality data available for genetic analysis
applications. Illumina CSPros undergo a rigorous two-phase certification process
that includes minimum data generation, data certification and on-site audit of
the facility and processes. For more information about the CSPro program, please
visit www.illumina.com/cspro .
About IntegraGen
IntegraGen is a pioneer in the field of predictive healthcare. The company
uses its unique genomic analysis expertise to identify genes associated with
complex diseases and commercializes molecular diagnostic tests to enable
individualized diagnosis, prevention and treatment.
IntegraGen’s proprietary gene mapping technology GenomeHIP provides fast,
reliable, and cost-effective discovery of genetic loci. Paired with strong
biostatistics, bioinformatics and fine mapping genotyping capabilities,
IntegraGen has successfully identified and patented genes associated with early
and late onset diseases. Efforts are currently focused on Type-2 Diabetes,
Obesity, Autism and Bi-Polar Disorder. Clinical trials for the company’s first
genetic test for autism, based on internally identified genes, were carried out
in Q1 2007.
Founded in July 2000, IntegraGen has 34 employees and is based in the French
Genopole of Evry, near Paris, France, in Bonn, Germany and in New York, USA.
More information can be found at
www.integragen.com .
About Illumina
Illumina is a leading developer, manufacturer and marketer of
next-generation life science tools and integrated systems for the large scale
analysis of genetic variation and biological function. Using our proprietary
technologies, we provide a comprehensive line of products and services that
currently serve the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers include
leading genomic research centers, pharmaceutical companies, academic
institutions, clinical research organizations and biotechnology companies. Our
tools provide researchers around the world with the performance, throughput,
cost effectiveness and flexibility necessary to perform the billions of genetic
tests needed to extract valuable medical information from advances in genomics
and proteomics. We believe this information will enable researchers to correlate
genetic variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier and permit better
choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: this release may contain forward-looking statements that involve risks and
uncertainties. Among the important factors that could cause actual results to
differ materially from those in any forward-looking statements are the costs and
outcome of Illumina's litigation with Affymetrix and our ability (i) to
integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop
and commercialize further our BeadArray(TM), VeraCode(TM) and Solexa(R)
technologies and to deploy new gene expression and genotyping products and
applications for our technology platforms, (iii) to manufacture robust micro
arrays and Oligator(R) oligonucleotides, (iv) to integrate and scale our
VeraCode technology, (v) to scale further oligo synthesis output and technology
to satisfy market demand derived from our collaboration with Invitrogen,
together with other factors detailed in our filings with the Securities and
Exchange Commission including our recent filings on Forms 10-K and 10-Q or in
information disclosed in public conference calls, the date and time of which are
released beforehand. We disclaim any intent or obligation to update these
forward-looking statements beyond the date of this release.
ENDS
Contacts:
Illumina
Maurissa Bornstein
Public Relations Manager, Illumina
+1 858.332.4055
mbornstein@illumina.com
Peter J. Fromen
Sr. Director, IR,Illumina
+1 858.202.4507
pfromen@illumina.com
IntegraGen
Emmanuel Martin
Director, Sales & Marketing, IntegraGen
+33 (0) 160 910 907
emmanuel.martin@integragen.com
For high resolution images please contact:
Katie Odgaard, Senior Account Executive
Northbank Communications
Tel: +44 (0)207 268 3243
Email: k.odgaard@northbankcommunications.com
| |
|
